reported that they would advise the patient to see a doctor. The most frequent comments made by pharmacists were about the commercial viability of screening in pharmacies and the lack of space available to ensure patient privacy and confidentiality during screening. Conclusions -Screening in retail pharmacies would probably be a commercial failure unless doctors were able to contract for screening services from pharmacies. Evidence from this study and others, however, leads us to question the desirability of this option.
The past few years have seen moves to extend the role of retail pharmacists beyond the traditional dispensing of medicines. The Nuffield Foundation Committee of Inquiry into Pharmacy, reporting in 1986,' and the government white paper on primary health care of the following year2 proposed extending the role of community pharmacists into health education and screening, increasing their role in advising about minor illness, supervising medication in nursing homes for the elderly, and advising general practitioners about cost effective prescribing. In 1990 a joint working party was set up between the Department of Health and the Royal Pharmaceutical Society "to consider ways in which the National Health Service community pharmaceutical services might be developed to increase their contribution to health care, and to make recommendations". The Table 4 shows the results of the question which asked for the pharmacists' reaction to an abnormal result on a screening test. Thirty three participants answered this question. All belonged to the group who offered screening currently or who might do so in future. Approximately half (16: 49%) reported that they would tell the patient of the abnormality. Thirty one (94%) reported that they would advise a patient to see his or her general practitioner in the event of an abnormal result, and the remaining two respondents (6%) reported that they would advise the patient to see another medical practitioner, in both cases a hospital consultant. Twenty eight (85%) stated that they would give the patient verbal or written advice upon the finding of an abnormality. Twenty seven (82%) reported that they would repeat the test.
Fifty four responded to the invitation to comment upon community pharmacy and upon screening within retail pharmacy. These comments are given in table 5. The most frequent comment received concerned the funding of screening. Fifteen of the 37 pharmacists currently offering screening or planning to do so in the future questioned its commercial viability in pharmacies, as did four of the 39 pharmacists not planning to offer screening. Ten of the 37 pharmacies offering screening currently or in future mentioned lack of space available to ensure patient privacy and confidentiality during screening, as did one of the 39 not planning to offer screening. Five of the 37 who offer screening currently or plan to do so in the future commented upon the lack of time or staff available to undertake screening, as did three of the 39 not planning to offer screening. A variety of other comments was made by smaller numbers of respondents, and included mention of the lack of public demand for screening, the need for training in counselling skills, and doubts as to whether screening was beneficial.
Seven of the nine individuals currently offering screening were able to be contacted by telephone. A list of their comments is provided in table 6 . Of particular interest were the Most general practitioners, in a survey of their attitudes to extended roles for community pharmacists, disagreed with the suggestions that pharmacists should screen for raised blood pressure, raised blood lipids, or height and weight in schoolchildren.'5 A recent meta-analysis of results of cholesterol lowering treatments concluded that "population screening for isolated raised cholesterol concentrations, whether in the high street or in the general practitioner's surgery, is not currently indicated".16 This is echoed in the recent Health of the Nation key area handbook on coronary heart disease and stroke, which recommended a case finding approach rather than systematic screening, with testing focused on priority groups with other risk factors for coronary heart disease. '7 This survey indicates that public interest in screening, particularly cholesterol screening, is low, and that funds would have to be made available either from central sources or from general practitioners to make it commercially viable. However, the lack of funding for health education activity in pharmacies has been commented upon previously,6 and it is unlikely that screening in pharmacies would be given central support. Moreover, the public may be right. It is questionable whether the provision of screening for coronary heart disease risk factors in retail pharmacies is either necessary or desirable.
